WellMedr review

WellMedr is the widest shelf in this part of the ranking and the hardest one to price, and both facts matter more than the score. Start with what is genuinely here, because it is a lot. Compounded semaglutide and tirzepatide, brand-name Ozempic and Zepbound at real published month-to-month figures of $1,399 and $1,599, and an eight-product microdose line with a page of its own — four oral and four injectable, pairing a GLP-1 with NAD+, B12, inositol, magnesium or L-theanine. That last part is the unusual one. Most programs that advertise microdosing sell you a smaller amount of the same injection; these are separate products with separate formulations, and four of them need no needle at all. If a low-dose or oral route is what you came for, very few providers in this ranking offer this much choice. WellMedr also does three things on disclosure that better-known names do not. The compounding caveat is on the pricing page, where you are deciding, rather than in a footer: compounded medications are "regulated by state Boards of Pharmacy, but are not evaluated by the FDA for safety or efficacy", with the thyroid C-cell and medullary thyroid carcinoma warnings printed beside it. The telehealth consent names the clinical group practicing medicine — OpenLoop Health, Inc. and its state professional corporations — so the entity behind your prescription is identifiable rather than implied. And it names the pharmacy: the privacy policy lists Mycelium Pharmacy as WellMedr's "U.S.-licensed fulfillment pharmacy", alongside OpenLoop as the medical group. Being able to see who prescribes your medication and who fills it is the single hardest thing to find in this category, and most of the programs in this ranking will not tell you either one. Note the exact claim, though: Mycelium is named as the pharmacy that fills the order, which is not quite the same as naming the 503A facility that compounds the drug, and WellMedr does not go that far. Credit where it is due; all three are better than this category's average. Now the price, which is the reason this row scores where it does. The plan cards advertise "Starting At $59 a month" for semaglutide and "Starting At $99 a month" for tirzepatide. Neither is a monthly rate. The site's own banner says so in as many words — "Lock In $200 OFF Every Month, or $59/mo on 12/month Plans — For Life" — so $59 is what you pay if you commit to twelve months. What the same plan costs month to month is published nowhere on this site. Not on the pricing page, not in the terms, not on the plan cards. Both plan buttons hand you off to a checkout that will not load until a plan has already been chosen, and the alternative plan page renders blank, so there is no path to a month-to-month number that does not run through a medical intake first. We have left both price cells reading "Not disclosed" rather than printing $59, because $59 is not a rate a reader can walk up and buy, and printing it would have put this company at the top of our cheapest-tracked lists on a price that does not exist without a year's commitment. Two smaller things compound that. A "month" here is four weeks: both plans state they ship every 4 weeks, which is thirteen charges a year rather than twelve, so the annual cost runs about 8.6% above what the monthly label implies, and the site never reconciles the two numbers. And the flat-dose promise covers one molecule only — "Same price regardless of dosage" is printed on the tirzepatide card, and the semaglutide card says nothing either way, so on semaglutide you simply do not know whether stepping up a dose steps up the bill. Only two of the eight microdose products publish any price at all, both $199 a month; the other six publish none. The most serious thing on this site is not a price. The microdose page headlines "ZERO Side Effects", with a subhead reading "Zero side effct for 70%+ of members" — their spelling — and it sits directly above that same page's own warning about thyroid C-cell tumors. A compounded GLP-1 has the side-effect profile of a GLP-1; nausea, vomiting and constipation are the ordinary experience of starting one, and no provider can promise their absence. The page contradicts itself within a single scroll, and a reader who believes the headline is a reader who will not recognize a real symptom when it arrives. Weigh that against the honest caveat on the pricing page, because both are this company's work. A few more things to know. Which states WellMedr can prescribe in is published nowhere, so whether it can treat you at all is not knowable before you start. "FDA-regulated pharmacies" in the top bar is a claim about the pharmacy, not the drug — the compounded medication is not FDA-approved, exactly as the pricing page's own caveat says. And the credibility case leans hard on borrowed authority: "Helping Over 550,000 People" and "used by 1,000,000+ patients" sit beside testimonials the site itself labels as "Inspired by real patient success stories in similar Telehealth programs" — that is, not its patients — with Dr. Nowzaradan, Kevin O'Leary, Russell Wilson and Ray Lewis carrying much of the rest. The disclosure on the testimonials is to WellMedr's credit; the patient counts standing next to them are not. Worth choosing if the microdose or oral line is the reason you are shopping, you want brand-name access on the same account, and you are prepared to complete an intake before you learn what you will actually pay. Skip it if you need to know the month-to-month price before you commit, or if a program that promises zero side effects above its own tumor warning is not one you want managing your medication.